Protocol is available at protocols.io (DOI: <http://dx.doi.org/10.17504/protocols.io.bfn4jmgw>). Data are available at Dryad (DOI: [10.5061/dryad.t76hdr7z5](https://doi.org/10.5061/dryad.t76hdr7z5)).

Introduction {#sec006}
============

Over the last two years, an increasing number of studies have reported complications related to breast silicone implants \[[@pone.0235050.ref001]--[@pone.0235050.ref004]\]. These complications are commonly associated with the incidence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) \[[@pone.0235050.ref005]--[@pone.0235050.ref012]\]; however, the onset of this pathology and its trigger point is yet to be elucidated.

Interestingly, many of these changes have been reported despite the macroscopic integrity of breast implants. The main clinical complications related to breast implants are breast stiffness, late seroma, lymph node enlargement, and silicone migration to distant organs. Also, clinical signs related to autoimmune reactions have been reported, which highlight the silicone implant incompatibility syndrome (SIIS) \[[@pone.0235050.ref013]\].

Gel bleeding is not virtually ignored, but, as far as we know, there are indeed no demonstrations that can determine any of the known complications.

Recently we have described a new radiological finding, silicone-induced granuloma of breast implant capsule (SIGBIC) \[[@pone.0235050.ref014]\], defined as granulation tissue formed from a reaction between the breast implant fibrous capsule and free silicone corpuscle due to bleeding of the intact breast implant. We have described 3 BMRI features that are irrevocable for this diagnosis: 1. black-drop signal; 2. mass with hyper signal at T2-weighted sequences; and 3. late contrast enhancement \[[@pone.0235050.ref015]\]. Besides, we described the physiopathology of the disease \[[@pone.0235050.ref016]\]. ([Fig 1](#pone.0235050.g001){ref-type="fig"}).

![Scheme of Silicone Induced Granuloma of Breast Implant Capsule (SIGBIC) development and its imaging findings.](pone.0235050.g001){#pone.0235050.g001}

This study aimed to determine the ability of BMRI to predict GB according to SIGBIC diagnosis with the three irrevocable features. We also compared the performance of SIGBIC to diagnose GB to the descriptors proposed by the BI-RADS lexicon. This manuscript is the first prospective study to determine its prevalence in clinical practice.

Materials and methods {#sec007}
=====================

This study was a prospective observational study conducted at a single academic institution with subspecialty training in breast imaging from March 2017 to August 2018 following local ethics committee regulations. We obtained free, written, informed consent from all patients. We evaluated patients referred for BMRI. All patients who had breast implants were included in the study. The exclusion criteria were patients with previous BMRI scans during the study period to avoid duplicity of the results, technically inappropriate scans, and scans without contrast injection. The research was deposit in protocols.io as <http://dx.doi.org/10.17504/protocols.io.bfn4jmgw>. The study was approved by the institutional ethical committee (Instituto Brasileiro de Controle do Câncer). Inform consent was obtained from all of the participants. Study protocol: Plataforma Brasil CAAE: 77215317.0.0000.0072.

We used a standard BMRI factory protocol for a 1.5-T imager (Magnetom Aera; Siemens Healthcare) with a dedicated eight-channel bilateral breast coil in the axial orientation. The acquired sequences were: 1. Axial T2-weighted fast spin-echo; 2. Sagittal Proton-density weighted; 3. Sagittal T2-weighted silicone selective that enhance the silicone signal; 4. Sagittal T2-weighted sequence with silicone suppression that extract the silicone signal; and 5. 4 following dynamic contrast sequences with fat suppression and reconstruction with subtraction.

One radiologist with 18 years of experience in BMRI read all the acquired images.

Three novelty imaging features were adopted for SIGBIC diagnosis:

1.  black drop signal: a marked focus of low signal at T1 sequences in the fibrous capsule, and a silicone signal focus could be associated in silicone sensitive sequences, without enhancement in post-contrast sequences;

2.  mass with hyper signal at T2 weighted sequence: an intracapsular mass that could misdiagnose as seroma

3.  late contrast enhancement: the mass (b) shows late contrast enhancement at the late phase.

SIGBIC diagnosis was only determined when all the three irrevocable features were present.

Also, and for comparison purposes, we described nine established BMRI findings according to the BI-RADS lexicon, considered as equivocal signs:

1.  Capsular contracture: increase of the anteroposterior diameter of the implant with fibrous capsule thickening and contrast enhancement (Figs [2](#pone.0235050.g002){ref-type="fig"},[3](#pone.0235050.g003){ref-type="fig"}, [4](#pone.0235050.g004){ref-type="fig"} and [5](#pone.0235050.g005){ref-type="fig"}).

2.  Intracapsular rupture: discontinuity of the breast implant surface, often characterized by subcapsular line, keyhole sign, teardrop sign, and linguine sign restricted to intracapsular space.

3.  Extracapsular rupture: discontinuity of the fibrous capsule with extravasation of the internal silicone contents.

4.  Water droplets: foci of water signal inside the intact breast implant inferring loss of surface permeability ([Fig 2](#pone.0235050.g002){ref-type="fig"}).

5.  Implant Rotation: posterior surface of the breast implant displacement, often identified by the ectopic position of the implant seal ([Fig 3](#pone.0235050.g003){ref-type="fig"}).

6.  Extracapsular Siliconoma: extracapsular free silicone without signs of fibrous capsule rupture.

7.  Enlarged intramammary lymph node (EILN): enlarged pericapsular intramammary lymph node ([Fig 4](#pone.0235050.g004){ref-type="fig"}). We used two criteria to determine EILN: smaller diameter greater than 0.5cm (perpendicular axis) and thickening of the lymph node cortex with reduced fatty hilum.

8.  Pericapsular edema: non-mass pericapsular enhancement ([Fig 5](#pone.0235050.g005){ref-type="fig"}).

9.  Intracapsular seroma: collection inside the fibrous capsule (Figs [2](#pone.0235050.g002){ref-type="fig"} and [3](#pone.0235050.g003){ref-type="fig"}).

![A 45-year-old woman 6 years after implant placement with left breast stiffness T2-weighted and silicone-sensitive images on the right and left, respectively.\
Blue and red arrows demonstrate an intracapsular seroma and mass that includes free silicone. (a) Intact breast implant. (b) Green arrow demonstrates water droplets.](pone.0235050.g002){#pone.0235050.g002}

![A 30-year-old woman who underwent an aesthetic procedure for silicone prosthesis four years ago, 1 week before an increase in volume and inflammation of the right breast.\
(a) STIR sequencing presented a massive intracapsular collection (red asterisk) with intact and rotated breast implant (green asterisk), and free silicone in the fibrous capsule forming the granuloma (yellow arrow). (b) Identical results were found with T2W silicone-sensitive, and after the use of contrast. (c) Findings were compatible with the black drop signal. Intact breast implant.](pone.0235050.g003){#pone.0235050.g003}

![A 62-year-old patient underwent right breast repair surgery three years ago, followed by treatment with radiotherapy sessions.\
Arthralgia had been reported for 3 months. (a) Intracapsular masses are shown in the pre-contrast sequence (green arrow), with enlarged intramammary lymph nodes (red arrow), and black-drop signal (yellow arrow). (b) The mass has late contrast enhancement (green line at the graph) compared to the lymph node early enhancement (blue line). The mass has a high signal at T2 weighted sequence, and the implant was intact.](pone.0235050.g004){#pone.0235050.g004}

![(a, b, c, d, e and f) A 37-year-old patient with a breast implant for 3 years, who showed a palpable mass in the medial quadrants of the left breast for 3 weeks.\
(a) T2W fat-suppressed imaging showing a capsular contracture with a hypersignal mass in the medial quadrant and pericapsular edema (yellow arrow). The post-contrast sequence shows the late enhancement of this mass (green curve) compared with the heart (blue curve). (b) A pericapsular enhancement is shown (yellow arrow). (c) Ultrasound with elastography shows siliconoma at the site *via* BMRI, characterized by a hard mass at and snowstorm artifacts (yellow arrow), with a small collection at the periphery (green arrow). (d) Mammography shows a pericapsular mass in the medial quadrant (yellow arrow). (e) Histology showing free silicone particles and inflammatory cells (magnification, 50×). Immunohistochemistry for T lymphocyte (CD3) positive. Intact breast implant.](pone.0235050.g005){#pone.0235050.g005}

Patients diagnosed with SIGBIC at BMRI underwent a second-look ultrasound scan using a device with a 7.5--14 MHz multi-frequency probe (Aplio 300, Toshiba). All the patients who met the SIGBIC BMRI diagnostic criteria and were symptomatic underwent US-guided percutaneous core-biopsy or directed for surgical capsulectomy. Symptomatic criteria for biopsy were: breast enlargement refractory to clinical treatment, local inflammatory signs, and ordinary daily activities limitation. We opted for the percutaneous biopsy in patients who have easy access to performing the procedures. In patients where the lesions were very deep or posterior to the breast implants, capsulectomy has opted. We performed percutaneous biopsy using a 14-G needle attached to an automatic biopsy gun. At least three samples were collected. The remaining BMRI equivocal findings were followed up.

The specimens from biopsies or surgical procedures were evaluated in the same institution, where a diagnosis of SIGBIC was confirmed when the silicone particle was observed at microscopy, as described in a previous study. ([Fig 6](#pone.0235050.g006){ref-type="fig"}).

![Examples of percutaneous breast biopsy in 2 patients.\
Patient 1 (A, B, C and B). A 49-year-old patient with aesthetic breast implants for 5 years. For 1 month she related breast enlargement with local inflammatory signs on her right breast; and Patient 2 (e, f, g and h). A 68-year-old patient who underwent adenomastectomy and breast reconstruction with breast implants followed to radiotherapy sessions for 1 year. She reported breast stiffness and peripheral arthralgia. At BMRI (A and E), findings suggestive of SIGBIC pointed by the yellow arrow. Ultrasound elastography (B and F) showing a hard mass at the fibrous capsule (green arrow). Biopsy of the mass (C and G) using first a fine needle aspiration to collect the intracapsular seroma (C) and core biopsy of the mass (G) represented by the white arrow. Histological specimens confirming silicone granuloma in red arrow (D,H). In patient 1 we can see intracellular silicone in histocytes (foamy histiocytes) in figure D, and extracellular silicone with giant cell in figure H. Often, intracapsular collection is reported in the presence of intracellular silicone (C,D).](pone.0235050.g006){#pone.0235050.g006}

The main objective of this study was to determine the ability of BMRI to predict gel bleeding in patients with SIGBIC diagnosis compared with histopathology as the gold standard. As secondary objectives, we established what equivocal BMRI features could be related to GB. In this context, a univariate analysis was performed through Chi-Square tests \[[@pone.0235050.ref017]\] and Fisher's Exact Test \[[@pone.0235050.ref018]\] and the test of Mann-Whitney \[[@pone.0235050.ref019]\] for the case of categorical variables \[[@pone.0235050.ref020]\]. The approach used was not the automatic Stepwise. Through the univariate analysis, we selected the potential predictors for the response variable, considering a level of significance equal to 25%, according to Kennedy and Bancroft criteria \[[@pone.0235050.ref021]\]. The multivariate Logistic Regression model was only used for patients with histopathological proved SIGBIC in order to determine diagnosis ability using ONLY the established BI-RADS lexicon BMRI features.

We also evaluated, in order to verify if the adjusted models were adequate and if they had functional predictive capacity, some measures of quality of adjustment using only the association of the main equivocal features (BI-RADS lexicon) for GB diagnosis: Pseudo R^2^ \[[@pone.0235050.ref022]\], AUC (area under the ROC curve), Sensitivity, Specificity, VPP, and the Hosmer-Lemeshow test \[[@pone.0235050.ref018]\]. The software used in the analysis was R (version 3.5.2).

Results {#sec008}
=======

We performed 2290 consecutive BMRI from March 2017 to August 2018. Of these, 736 patients had breast implants. Fifty-six patients were excluded from the study, 48 because they refused the injection of contrast medium, six because the presence of motion artifacts or difficulty in performing the silicone sequences, and two dues to previous BMRI scans during the study period. We also excluded 472 patients without the three diagnostic criteria for SIGBIC (equivocal features).

The remaining 208 patients with SIGBIC diagnosis by BMRI (irrevocable signs) were included in the study. All 208 patients with the irrevocable findings had GB confirmed by silicone corpuscles in histopathology. Histological specimens of 40 (19.9%) cases were obtained by surgical capsulectomy and 168 (80.1%) from percutaneous breast biopsy. There were no false-positive results of GB adopting the SIGBIC irrevocable criteria. All capsular specimens showed silicone particles associated with the inflammatory response at histology, and all patients submitted to surgical capsulectomy have no apparent signs of implant rupture. We did not report any complications related to percutaneous breast biopsy.

The results for the equivocal features, described by the BI-RADS lexicon to diagnose GB were as follows:

Univariate analysis {#sec009}
-------------------

[Table 1](#pone.0235050.t001){ref-type="table"} shows the univariate analysis using the Chi-Square test \[[@pone.0235050.ref017]\] for categorical explanatory variables with expected frequencies higher than 5 in all class and Fisher's exact test \[[@pone.0235050.ref017]\]. The equivocal features with to predict GB diagnosis were: water droplet, enlarged intramammary lymph node, pericapsular edema, and intracapsular seroma. We adopted a statistical significance of p\<0.001. The variable capsular contracture did not participate in this analysis since it was present in all patients.

10.1371/journal.pone.0235050.t001

###### Univariate analysis of breast MRI features.

![](pone.0235050.t001){#pone.0235050.t001g}

  Variables                                 Category   SIGBIC (+)   P-value   
  ----------------------------------------- ---------- ------------ --------- ---------------------------------------------------
  Capsular Contracture                      (-)        0            0         **\<0.001**[^2^](#t001fn002){ref-type="table-fn"}
  (+)                                       208        30.6%                  
  Intracapsular Rupture                     (-)        207          100.0%    \-
  (+)                                                                         
  Extracapsular Rupture                     (-)        208          30.8%     0.319[^2^](#t001fn002){ref-type="table-fn"}
  (+)                                       0          0.00%                  
  Water droplet                             (-)        142          25.7%     **\<0.001**[^1^](#t001fn001){ref-type="table-fn"}
  (+)                                       66         51.97%                 
  Implant Rotation                          (-)        198          31.2%     0.274[^1^](#t001fn001){ref-type="table-fn"}
  (+)                                       10         22.2%                  
  Siliconoma Extracapsular                  (-)        207          30.6%     1.000[^2^](#t001fn002){ref-type="table-fn"}
  (+)                                       1          25.0%                  
  Enlarged Intramammary Lymph Node (EILN)   (-)        179          28.3%     **\<0.001**[^1^](#t001fn001){ref-type="table-fn"}
  (+)                                       29         60.4%                  
  Pericapsular edema                        (-)        179          27.9%     **\<0.001**[^1^](#t001fn001){ref-type="table-fn"}
  (+)                                       29         74.4%                  
  Intracapsular seroma                      (-)        166          27.7%     **\<0.001**[^1^](#t001fn001){ref-type="table-fn"}
  (+)                                       42         51.2%                  

^1^Chi-Square test.

^2^Fisher's Exact test.

^3^Mann-Whitney test

SIGBIC: silicone induced granuloma of breast implant capsule

Multivariable analysis {#sec010}
----------------------

A multivariate model of Logistic Regression \[[@pone.0235050.ref017]\] was adjusted from the variables selected in the univariate analysis, and for this model, the Backward method was applied for the final selection of the variables, considering a significance level of 5%.

[Table 2](#pone.0235050.t002){ref-type="table"} presents the final multivariate model for the GB variable with the equivocal features described by the BI-RDADS lexicon. When positive an individual has the chance to have GB multiplied by 2.8 \[1.8; 4.4\] in the presence of water droplet, 3.07 \[1.5; 6.1\] in the presence of enlarged intramammary lymph node, 5.02 \[2.3; 11.1\] in the presence of pericapsular edema, and 2.4 \[1.4; 4.1\] for intracapsular seroma.

10.1371/journal.pone.0235050.t002

###### Multivariate analysis associating BMRI variables with and without gel bleeding.

![](pone.0235050.t002){#pone.0235050.t002g}

  Variables                                O.R.            C.I. (95%)    P-value
  ---------------------------------- ----- --------------- ------------- ---------
  Water droplet                      (-)   1.0             \-            \-
  (+)                                2.8   \[1.8; 4.4\]    **\<0.001**   
  Enlarged Intramammary Lymph Node   (-)   1.0             \-            \-
  (+)                                3.1   \[1.5; 6.1\]    **0.001**     
  Pericapsular edema                 (-)   1.0             \-            \-
  (+)                                5.0   \[2.3; 11.1\]   **\<0.001**   
  Intracapsular Seroma               (-)   1.0             \-            \-
  (+)                                2.4   \[1.4; 4.1\]    **0.001**     

O.R. odds ratio

C.I. confidence interval

[Table 3](#pone.0235050.t003){ref-type="table"} shows the negative predictive value (NPV), Hosmer-Lemeshow test, and Pseudo-R2 test for the determination of GB for the final model adopting the most statistically significant equivocal BMRI features. It should be noted that: the area under the ROC curve (AUC) of the final model was 0.750, and the Pseudo-R2 was 24.79%. The Hosmer-Lemeshow test for the final model indicated that the fit of the model was adequate (p-value = 0.795).

10.1371/journal.pone.0235050.t003

###### Quality statistics of the multivariate model for GB diagnosis adopting water droplets, enlarged intramammary lymph nodes, pericapsular edema and intracapsular seroma.

![](pone.0235050.t003){#pone.0235050.t003g}

  SEN     SPE     PPV     NPV     Accuracy   AUC     Hosmer-Lemeshow   Pseudo-R^2^
  ------- ------- ------- ------- ---------- ------- ----------------- -------------
  0.740   0.638   0.474   0.848   0.669      0.750   0.795             24.79%

SEN: sensitivity

SPE: specificity

PPV: positive predictive value

NPV: negative predictive value

AUC: area under curve

Discussion {#sec011}
==========

Currently, silicone bleeding is virtually ignored as a possible trigger factor for complications related to silicone implants. Most articles illustrate silicone bleeding as a rare event and of little clinical relevance. They justify this statement due to the evolution of silicone breast implants, especially with the use of cohesive gel.

Since the description of SIGBIC by our group, we observed an increasing prevalence of SIGBIC in our clinical practice; therefore, we conducted this prospective study to determine BMRI ability to predict GB in patients with SIGBIC diagnosis. We also intended to assess the association between BMRI equivocal features described by the latest BMRI BI-RADS lexicon and SIGBIC in predicting GB.

Reported breast implant-associated complications have recently been increasing, including BIA-ALCL and Breast Implant Illness in academia, mainstream, and social media. Despite the reported severity associated with anaplastic lymphoma, the number of cases described in the literature remains small, with \<750 cases reported, minimizing its relevance \[[@pone.0235050.ref011],[@pone.0235050.ref012]\]. Furthermore, the trigger point to develop this pathology remains unclear.

We recently described the radiological findings of a granuloma developed in the intracapsular compartment of breast implants that was formed by an immune response of the fibrous capsule to the free silicone particles bleeding from intact breast implants \[[@pone.0235050.ref016]\]. After a certain time or when subjected to stress situations (like heat and trauma), all breast implants may alter the surface permeability and may present gel bleeding of the internal contents or leakage of the shell \[[@pone.0235050.ref001]\]. Both the silicone and saline implant have the substance polydimethilsilixonase (PDMS) as a shell component. Some researchers speculated that this substance could elicit an immune response when in contact with the fibrous capsule. Some patients have a higher risk of developing an immune response, for example, those with SIIS. SIIS clinical manifestations may vary and depend on the intensity of the inflammatory reaction of the host. \[[@pone.0235050.ref016]\].

In our study, 30.6% of patients with breast implants referred for BMRI scan at our facility fulfill the irrevocable BMRI criteria for SIGBIC diagnosis. All these cases were confirmed by histopathology by the presence of silicone corpuscles.

Due to the novelty of the study, we chose very restrictive criteria for the SIGBIC diagnosis. We aimed to avoid false-positive results in this context. The black-drop signal consists of a giant cell reaction to a foreign body in the fibrous capsule. The mass with hyper signal at the T2-weighted sequence is the development of granulation tissue in the contacted area between the silicone corpuscle and the fibrous capsule. Finally, the late contrast enhancement appears because of the poor intracapsular vascularization. This poor vascularization is due to the fibrous capsule protective barrier. Mass with contrast enhancement could differentiate the granuloma from the intracapsular seroma. When the three SIGBIC diagnosis criteria were met, we could predict GB in all cases. Adopting this diagnosis criteria, we did not have false-positive results.

We found a statistically significant association between GB and some of the equivocal BMRI BI-RADS lexicon features. Capsular contracture, water droplets, enlarged intramammary lymph node, pericapsular edema, and intracapsular seroma were associated with GB. When used the Hosmer-Lemeshow test and pseudo-R2 to associate the presence of GB with only the equivocal BMRI features, we found good sensitivity, specificity, and diagnostic accuracy. These findings could support the hypothesis that GB is underdiagnosed in our clinical practice, where most of the articles state that it is a rare event.

Analyzing the ROC curve adapting the equivocal findings proposed by the BI-RADS lexicon, we observed a good diagnostic accuracy (ROC AUC = 0.750). However, if we adopt the three specific criteria for the SIGBIC diagnosis proposed by our study, we can determine GB in 100% of patients. We believe that the proposed criteria could be incorporated into the BI-RADS lexicon to perform the diagnosis of GB with better diagnostic performance.

We hypothesized that the water droplets finding are related to permeability loss in the breast implant shell. When intracapsular fluid enters through the implant shell, a chemical reaction occurs with the inside silicone content or the silicone-made surface of the implant, which leads to silicone residues into the intracapsular compartment. Water-droplet corresponds to a macroscopic diagnosis, where the naked eye can perform the diagnosis by BMRI. We speculated that the water-droplets diagnosis by BMRI might be underestimated if compared with microscopy. ([Fig 7](#pone.0235050.g007){ref-type="fig"}) These findings were similar to those described as: *\"breast implants*, *from clear to cloudy\"* \[[@pone.0235050.ref023],[@pone.0235050.ref024],[@pone.0235050.ref025]\], where the authors report color changes of intact breast implants due to a chemical reaction with intracapsular fluid. In our study, when water droplets are present, the risk of SIGBIC is increased in 2.82.

![Correlation between water droplets at BMRI and microscopy of implant shell.\
At BMRI (a) is possible to see a focal signal change inside the breast implant pointed by the blue arrow. At the microscopy evaluation of implant shell (b) is possible to note silicone leakage pointed by the red arrow. Inside the implant with a 1.600-fold microscopy (c) it is possible to see the water droplets formed from a chemical reaction between the intracapsular fluid and the silicone gel content.](pone.0235050.g007){#pone.0235050.g007}

We observed a high prevalence of GB in our study. Interestingly, no previous study regarding BMRI silicone implant findings has reported this occurrence neither the relation to GB. There may be different reasons for this. First, culturally most BMRI protocols for breast implant evaluation are performed without the use of contrast media. This factor may lead to a misdiagnosis of SIGBIC as a late seroma. Second, there may be a lack of diagnostic expertise. For example, before 2017, our service had not reported a positive diagnosis of SIGBIC. However, some patients were diagnosed with SIGBIC during the study period, following persistent clinical complaints, and when comparing to previous exams, we could retrospectively diagnose SIGBIC.

The two excluded patients in our study were patients with clinical complaints related to breast implants with a previous BMRI without abnormalities reported. The patients underwent a new BMRI scan in our service, where we perform the diagnosis of SIGBIC. Since our study was to establish the prevalence of SIGBIC in patients who performed the BMRI scan in a prospective study, we opted to exclude patients with previous scans forwarded to a new BMRI scan.

The relevance of this manuscript is the novelty of the issue and to alert to the possibility of gel bleeding as a precursor to complications inherent to silicone breast implants. The results exhibit a high frequency of gel bleeding in this study when adopting the restricted proposed criteria for diagnosis.

Currently, patients with clinical complaints related to breast implants, either had a diagnosis of BIA-ALCL or were considered to be an idiopathic evolutionary change without a specific causal factor. The SIGBIC diagnosis impacts patient care is in light of the high prevalence of these findings in our society. The SIGBIC diagnosis helped the patients to choose the best management of the disease focused on the trigger point of its development. Notably, the diagnosis discards the psychological origin of the symptoms which haunted many of these patients. Many patients in our clinical practice opted to breast explantation that evolves with clinical complaints remission.

This study has limitations. First, we only evaluated diagnostic BMRI in a single center. Future prospective multicenter studies should be conducted to confirm our findings. We are initiating a multicenter study involving three different breast diagnostic centers to validate our results. An additional limiting factor was that only patients diagnosed with SIGBIC underwent percutaneous biopsies or surgical capsulectomies. Although, all patients had clinical indications for the procedure. As an observational study, it was not accepted by our ethical committee to have a control group submitted to breast biopsy. However, we were able to illustrate that MRI can diagnose GB, the novelty of this study. Future studies should access the histology of patients with capsular contracture to search for free silicone in the fibrous capsule and correlate to clinical complaints. It is essential to emphasize the importance of pathologist and radiologist training to diagnose SIGBIC.

Our study supports that the three irrevocable SIGBIC criteria proposed by the authors could predict GB in the BMRI scan. It also supports that some equivocal BMRI features proposed by the BI-RADS lexicon are related to GB. Based on our findings, we suppose GB is underdiagnosed in clinical practice and could explain most of the silicone implant reported complications.

Supporting information {#sec012}
======================

###### 

(PDF)

###### 

Click here for additional data file.

BIA-ALCL

:   breast implant-associated anaplastic large cell lymphoma

BMRI

:   breast magnetic resonance imaging

GB

:   gel bleeding

SIGBIC

:   silicone-induced granuloma of breast implant capsule

SIIS

:   silicone implant incompatibility syndrome

10.1371/journal.pone.0235050.r001
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Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: General impression:

the topic of this manuscript is relevant and is approached with a strong clinical focus. It is a niche rather than a mainstream topic. The authors are preparing their material very comprehensively. They can rely on a very large expertise and number of patients.

I am convinced that the material and the core message are worthy of publication. However, in my opinion this is difficult to do in the current form of the manuscript.

First of all, this is due to the language style: there are many difficult to understand phrases.

In addition, the structure often does not follow the established criteria of such studies. For example, the rational is only defined late in the material and methods section. Explanations that belong in the latter are presented in results and so on. a restructuring and rewriting according to STARD criteria is strongly recommended.

In addition, I think the analysis of the data is too complex and the presentation of the results is hardly comprehensible. In the end, the statement is simple. Can we make a reliable diagnosis with additional diagnostic criteria? If so, how exactly? On the other hand, there are too many and too complex analyses, the details even appear to be erroneous (percentages Table 1) and in some cases are not necessary to convey the message of the authors. More important details such as the multivariate model and the ROC curve, however, are not mentioned at all.

Detailed comments

The abstract should be shortened . The methods have to be better defined here and the rational has to be better explained.

In the M&M, the setting of the hospital according to the STARD criteria should be better explained.

A clear description of the mri protocol is missing

I find the image material well prepared, however, on page 14, line 116 ff. the features should be supplemented with an example image + schematic drawing

Examples of incomprehensible wording can be found on page 15, lines 198 and 199

I do not consider it appropriate to set alpha at 25%.

in order to better examine the accuracy of the criteria, I suggest that patients +/- SICBIG to be analysed more consistently

The three patients who had to be excluded should be described in more detail

confusing is the moderate accuracy of multivariate models in the context of the otherwise very optimistic univariate results

Reviewer \#2: The paper is nicely written but I would suggest to better emphasize what should be the clinical consequence of these findings. I also find quite difficult to justify that the authors performed percutaneous breast biopsy or even capsulectomy for no suspicious findings, especially considering the risk to damage the implant. I would also suggest to improve the figure descriptions that are quite crucial to understand what the authors refer to.

Introduction

"However, gel bleeding is virtually ignored by the academy as a trigger point for these changes. Most articles advocate that gel bleeding is a rare event with no pathological significance. There are no studies in the literature demonstrating the frequency of this event in BMRI scans. "

I would rephrase this sentence. Gel bleeding is not virtually ignored but, as far as I know, there are indeed no demonstrations that it can determine any of the known complications.

M&M

How could you justify the biopsy or even the capsulectomy of these no suspicious findings also considering the not negligible risk to damage the implant? please specific better the criteria

EILN: I guess 0.5 cm is a quite low cut-off especially in the axillary/ periprosthetic tissue. Please comment.

Results

Fig. 2 Could you find a sonographic finding correlating to the MRI finding?

Fig.3 What is the curve referring to? Please describe more in detail the figures.

Fig.5 Please report separately the two cases and describe more in detail the figures (MRI sequence, finding, etc.)

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0235050.r002
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Silicone Induced Granuloma of Breast Implant Capsule (SIGBIC) diagnosis: Breast Magnetic Resonance (BMR) ability to detect silicone bleeding.

PLOS ONE

Dear Dr Fleury,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jun 01 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

ADDED

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.

• A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.

• An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Pascal A. T. Baltzer, M.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

1\. In the ethics statement in the Methods and online submission information, please specify the type of informed consent that was obtained from the participants (for instance, written or verbal, and if verbal, how it was documented and witnessed). OK

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

Hope the new version is adequate for publishing in PLOS ONE.

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

Revised the methodology.

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

Added to protocols.io

dx.[doi.org/10.17504/protocols.io.bfn4jmgw](http://doi.org/10.17504/protocols.io.bfn4jmgw)

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

Revised

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: General impression:

the topic of this manuscript is relevant and is approached with a strong clinical focus. It is a niche rather than a mainstream topic. The authors are preparing their material very comprehensively. They can rely on a very large expertise and number of patients.

I am convinced that the material and the core message are worthy of publication. However, in my opinion this is difficult to do in the current form of the manuscript.

First of all, this is due to the language style: there are many difficult to understand phrases.

In addition, the structure often does not follow the established criteria of such studies. For example, the rational is only defined late in the material and methods section. Explanations that belong in the latter are presented in results and so on. a restructuring and rewriting according to STARD criteria is strongly recommended.

In addition, I think the analysis of the data is too complex and the presentation of the results is hardly comprehensible. In the end, the statement is simple. Can we make a reliable diagnosis with additional diagnostic criteria? If so, how exactly? On the other hand, there are too many and too complex analyses, the details even appear to be erroneous (percentages Table 1) and in some cases are not necessary to convey the message of the authors. More important details such as the multivariate model and the ROC curve, however, are not mentioned at all.

Dear revisor, Thank you for the very important commentaries. I am convinced they improved the quality of the manuscript and made the manuscript more readable. Hope in this new version it fits the criteria for publishing in PLOS ONE.

I followed the STARD 2015 protocol.

Detailed comments

The abstract should be shortened . The methods have to be better defined here and the rational has to be better explained.

Rewritten

In the M&M, the setting of the hospital according to the STARD criteria should be better explained.

Explained

A clear description of the mri protocol is missing

This is the standard MRI protocol, available at protocols.io (dx.[doi.org/10.17504/protocols.io.bfn4jmgw](http://doi.org/10.17504/protocols.io.bfn4jmgw))

I find the image material well prepared, however, on page 14, line 116 ff. the features should be supplemented with an example image + schematic drawing Added.

Examples of incomprehensible wording can be found on page 15, lines 198 and 199

Excluded

I do not consider it appropriate to set alpha at 25%.

I QUESTIONED THE STATISTICS AND HE EXPLAINED ME TO ADOPT THIS APLHA AS IS CITED IN REFERENCES.

in order to better examine the accuracy of the criteria, I suggest that patients +/- SICBIG to be analysed more consistently

The three patients who had to be excluded should be described in more detail

EXPLAINED IN DISCUSSION

confusing is the moderate accuracy of multivariate models in the context of the otherwise very optimistic univariate results

THE ACCURACY IS MODERATE/ GOOD BECAUSE THE EQUIVOCAL FINDINGS WHERE NOT SPECIFIC FOR GB. WE ADOPTED THE CURRENT BI-RADS DESCRIPTORS TO PREDICT GB

Reviewer \#2: The paper is nicely written but I would suggest to better emphasize what should be the clinical consequence of these findings. I also find quite difficult to justify that the authors performed percutaneous breast biopsy or even capsulectomy for no suspicious findings, especially considering the risk to damage the implant. I would also suggest to improve the figure descriptions that are quite crucial to understand what the authors refer to.

THANK YOU FOR THE COMMENTS. THEY CONTRIBUTE TO ENHANCE THE POWER OF MY MANUSCRIPT.

Introduction

"However, gel bleeding is virtually ignored by the academy as a trigger point for these changes. Most articles advocate that gel bleeding is a rare event with no pathological significance. There are no studies in the literature demonstrating the frequency of this event in BMRI scans. "

I would rephrase this sentence. Gel bleeding is not virtually ignored but, as far as I know, there are indeed no demonstrations that it can determine any of the known complications.

PERFECT IT IMPROVES THE SOUNDNESS OF THE ARTICLE

M&M

How could you justify the biopsy or even the capsulectomy of these no suspicious findings also considering the not negligible risk to damage the implant? please specific better the criteria.

ADDED PATIENTS WITH SPECIFIC SYMPTOMS. WE ALSO REPORT THAT WE DIDN'T HAVE ANY COMPLICATION REGARDING BIOPSY.

EILN: I guess 0.5 cm is a quite low cut-off especially in the axillary/ periprosthetic tissue. Please comment.

WE ADOPTED FOR INTRAMAMMARY LYMPH NODE THE CUT OF OF 0.5CM IN THE PERPENDICULAR AXIS, WE ADDED THIS INFORMATION TO THE MANUSCRIPT.

Results

Fig. 2 Could you find a sonographic finding correlating to the MRI finding?

YES. IN THIS ARTICLE WE DESCRIBED SOME ULTRASOUND FEATURES. I described some specific features in figures 4 and 5.

Application of Breast Ultrasound Elastography to Differentiate Intracapsular Collection from Silicone-Induced Granuloma of Breast Implant Capsule Complementarily to Contrast-Enhanced Breast Magnetic Resonance Imaging

Fig.3 What is the curve referring to? Please describe more in detail the figures.

OK

Fig.5 Please report separately the two cases and describe more in detail the figures (MRI sequence, finding, etc.)

OK

10.1371/journal.pone.0235050.r003
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Dear Dr. Fleury,

Dear colleague!

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Pascal A. T. Baltzer, M.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Please do very carefully proofread your article. Being not a native english speaker myself, I understand that the manuscript is not free of small typographic and idiomatic mistakes, but there are some ackward typos (pos instead of post in a figure, some pseudo-english technical terms) I would strongly suggest you to correct in the prior to production.
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Silicone Induced Granuloma of Breast Implant Capsule (SIGBIC) diagnosis: Breast Magnetic Resonance (BMR) sensitivity to detect silicone bleeding.

Dear Dr. Fleury:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Pascal A. T. Baltzer

Academic Editor

PLOS ONE
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